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Industry Testing of Toxic
Pesticides on Human Subjects
Concluded “No Effect,”
Despite the Evidence
The National Academy of Sciences (NAS)
convened a panel of scientists in early 2003
to advise the U.S. Environmental Protection
Agency (EPA) on the scientific and ethical
issues surrounding the use of toxicologic
studies conducted by third parties on human
subjects (NAS 2003). These studies are gen-
erally sponsored by chemical manufacturers
to provide data for setting regulatory stan-
dards or for registering chemicals for com-
mercial use. The test substance is frequently
a pesticide or industrial chemical with no
medicinal value. Studies of the pesticides
dichlorvos (DDVP) and aldicarb are illustra-
tive. The sponsors’ intent was to force the
U.S. EPA to consider these data for setting
exposure standards (Mitka 2003).
DDVP, an organophosphate pesticide,
exerts its toxicity through inhibition of
acetyl cholinesterase. Symptoms of poison-
ing include diarrhea, vomiting, salivation,
convulsions, and—in extreme cases—
death. DDVP is widely used in pesticide-
impregnated resin strips. It is listed as a possi-
ble human carcinogen by the International
Agency for Research on Cancer (IARC 1991)
and a probable human carcinogen by the
U.S. EPA (1994). The AMVAC Chemical
Corporation submitted a report to the U.S.
EPA titled Dichlorvos: A Single Blind,
Placebo Controlled, Randomized Study to
Investigate the Effects of Multiple Oral Dosing
on Erythrocyte Cholinesterase Inhibition in
Healthy Male Volunteers (AMVAC 1997).
According to the report, subjects were given
21 daily oral doses of 7 mg dichlorvos (six
subjects), or placebo (three subjects). A
venous blood sample was taken every
2–3 days, immediately before dosing. The
authors (AMVAC 1997) reported that,
compared with the group mean predose
cholinesterase activity, 
The repeated measures analysis of variance
[ANOVA] showed statistically significant differ-
ences from the placebo group (1% level) on days
7, 11, 14, 16, and 18.
Despite these reported effects, the study
concluded that “none of these differences
were considered to be of biological signifi-
cance” and that “a no observed effect level
was established at 7 mg dichlorvos (equiva-
lent to approximately 0.1 mg/kg/day for a
70 kg male) …” (AMVAC 1997). The con-
clusion attempted to dismiss the measured
effects on cholinesterase inhibition by the
poorly substantiated assertion that no rele-
vant biological consequences would be
expected at this level of inhibition, whereas
the only biological end point measured in
the study was cholinesterase inhibition, and
this was significantly inhibited. 
Aldicarb, a carbamate pesticide, also
exerts its toxicity through acetyl cholines-
terase inhibition. Allowable levels of aldicarb
on food were set by the U.S. EPA in 1977,
based on data from an unpublished report
by Union Carbide (Haines 1971). Union
Carbide tested three groups of four healthy
adult males (at 0.025, 0.05, and 0.1 mg
aldicarb per kilogram body weight, with no
placebo or control group), and determined
that, on the basis of subclinical blood
cholinesterase inhibition, 0.025 mg/kg
aldicarb was the lowest dose having an effect
(lowest observed effect level; LOEL). From
this study the U.S. EPA set a no observed
effect level (NOEL; the maximum dose hav-
ing no effect) for cholinesterase inhibition of
0.01 mg/kg/day (National Research Council
1997) (Figure 1). Subsequent food poison-
ing incidents, however, demonstrate the
danger of reliance on such studies. In 1990,
Goldman et al. (1990) published a report of
three aldicarb food-poisoning incidents. The
LOEL was 0.0023 mg/kg, observed in a 66-
year-old woman after she consumed conta-
minated cucumber (Figure 1). Goldman et
al. (1990) reported that “within 45 minutes
she experienced nausea, vomiting, sweating,
dizziness, loss of balance, disorientation, and
fatigue.” Most estimated dosages resulting in
adverse effects were well below the
0.025 mg/kg LOEL reported by Union
Carbide (see study comparison in Figure 1).
Following the food-poisoning incident,
Rhone-Poulenc (Lyon, France) took over the
registration of aldicarb. It then sponsored a
single oral dose, double-blind placebo-
controlled study with human subjects (Wyld
et al. 1992) using the following doses:
placebo (16 males, 6 females), 0.01 mg/kg
(8 males), 0.025 mg/kg (8 males, 4 females),
0.05 mg/kg (8 males, 4 females), and
0.075 mg/kg (4 males). Wyld et al. (1992)
reported that red blood cell cholinesterase
activity was statistically significantly
depressed at all doses compared with the
placebo group (repeated measures ANOVA,
two-tailed, 5% significance level). Despite a
total of 24 adverse events reported by sub-
jects (localized sweating, lightheadedness,
headache, salivation), the authors reported
that only one event was treatment related
(profuse sweating in the highest dose
group). Wyld et al. (1992) reported that
there were no treatment-related clinical
symptoms at doses ≤ 0.05 mg/kg (the study
NOEL), a dose that was severe enough to
require hospitalization and atropine treat-
ment for one person in the California food-
poisoning incident (Goldman et al. 1990). 
A study of a handful of healthy adult
subjects is inadequate to determine the
expected response to toxic chemical expo-
sures from population diverse in ethnicity,
life-stage, sex, health status, genetic makeup,
metabolism, and nutritional status. Such
studies often lack enough subjects to provide
adequate statistical power to detect an effect
if it is present (Bekelman et al. 2003). When
studies are sponsored by chemical manufac-
turers with a financial interest in the study
outcome, the studies may be biased in
design and in interpretation. Efforts by the
chemical manufacturers to foist these scien-
tifically misleading studies on the U.S. EPA
in order to weaken regulatory standards is
profoundly troubling.
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Figure 1. A comparison of the NOEL and LOEL from
three separate studies of human exposure.
aWyld et al. (1992). bHaines (1971).
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Study Criticisms Unjustified
Sass and Needleman question the scientific
value of data from human studies sponsored
by the product’s manufacturer. They also
state that studies conducted by third parties
on human subjects should not be consid-
ered. They base this on their disagreement
with some of the interpretive statements in
the “Discussion” of the AMVAC report on
dichlorvos (AMVAC 1997). 
We disagree with their assessment for
several reasons. First, human data are recog-
nized by regulatory agencies and the scien-
tific community as the most relevant data
for assessment of human risk of harm
[International Programme on Chemical
Safety (IPCS) 2002; U.S. Environmental
Protection Agency (EPA) 1989, 1993, 1994,
2002, 2003; World Health Organization
(WHO) 1994, 2001). Sass and Needleman
do not provide any authoritative reference
for the automatic dismissal of third-party
human data they propose. Data from labo-
ratory animals used in toxicologic assess-
ments are useful, but as a large cooperative
study by the pharmaceutical industry has
recently shown, animal data are prone to
false-negative and false-positive results, sig-
nificantly limiting their ability to predict
human toxicities (Olson et al. 2000). 
The validity and ethicality of the data
from any study are not determined by the
identity of the study’s sponsor, the potential
uses of the material being tested, or the
author’s affiliation; to do so would be arbi-
trary and without scientific merit. Studies
should be considered if they are validly
designed and implemented according to
scientific and ethical standards of their time.
The study on dichlorvos (AMVAC 1997),
cited by Sass and Needleman, was con-
ducted in accordance with the Declaration
of Helsinki, including all amendments up to
and including the Hong Kong revision of
1989 (World Medical Association 2002).
Further, it followed the U.K. Principles of
Good Laboratory Practice (Her Majesty’s
Stationery Office 1999), it was performed in
accordance with the Organisation for
Economic Co-operation and Development
(OECD) Principles of Good Laboratory
Practice (OECD 1998) and the require-
ments of the European Commission (1986,
1988). The fact that the AMVAC study
complied with these practices was stated in
the report (AMVAC 1997), but this was not
mentioned by Sass and Needleman. Both
the ethics and the scientific validity are
established by meeting such stringent
requirements. 
Sass and Needleman incorrectly state
that cholinesterase inhibition was the only
biological end point measured in the study
(AMVAC 1997). Signs and symptoms were
obtained from the individuals on a daily
basis, and the study was conducted under
medical supervision requiring daily visits to
the laboratory by each participant. In addi-
tion, medical assessments, including clinical
chemistries, hematology, blood pressure,
electrocardiograms, and lung function tests,
were carried out before and after the study.
We are not aware of any studies that
demonstrate an effect more sensitive than
blood cholinesterases at very low doses of
dichlorvos. Sass and Needleman do not cite
any scientific study in support of their alle-
gation that some adverse effect would have
been missed at the dose tested. 
It is the regulatory agencies and the scien-
tists that work for them who evaluate study
results and make regulatory conclusions based
upon them, not the laboratory performing
the work, the study director, or the company
sponsoring the study. 
The AMVAC study shows a slight effect
on red blood cell (RBC) cholinesterase that
develops over the course of the study with
maximal mean group inhibition of 16%
measured at day 18, the last day RBC
cholinesterase was measured (AMVAC
1997). The first sentence of the “Discussion”
(AMVAC 1997) clearly states: 
The results from this study showed that multiple
oral dosing of dichlorvos (7 mg/kg, approxi-
mately 0.1 mg/kg/day) for 21 days caused some
inhibition of erythrocyte cholinesterase activity.
This statement is consistent with the
U.S. EPA review of the study (U.S. EPA
1998), AMVAC’s interpretation of the data
(AMVAC 1997), and the findings from
other published studies (Funckes et al. 1963;
Menz et al. 1974; Slomka and Hine 1981).
RBC cholinesterase values vary day to
day, and any lower value cannot be assumed
to be caused by the study chemical. In the
AMVAC dichlorvos study (AMVAC 1997),
before exposure began, RBC cholinesterase
varied ≥ 20% day to day in the same indi-
viduals. In the controls, variability was
apparent during the study; one individual
had a statistically significant lower RBC
cholinesterase on day 16 of the study but
had not been exposed to dichlorvos. 
The “Discussion” (AMVAC 1997)
addressed how the slight level of RBC inhi-
bition observed during the study might be
interpreted in light of the lack of any adverse
clinical findings. The conclusion did not
attempt to “dismiss the results,” and the
interpretation regarding the biological sig-
nificance of effects was undertaken in the
context of international guidelines and pub-
lished data on the significance of RBC
cholinesterase inhibition. The WHO has
stated that RBC cholinesterase inhibition
< 25% is evidence of exposure but not of a
hazard (WHO 1986). Similar interpreta-
tions have been published that indicate RBC
cholinesterase inhibition > 30% demon-
strates an adverse effect (Gallo and Lawryk
1991; Lotti 2001).
The AMVAC study (AMVAC 1997) did
not attempt to determine the response from
a diverse population, and no attempt was
made to state this as an objective or a conclu-
sion. However, there are published studies
showing the response in a variety of patients
in clinical studies conducted to evaluate the
possible medicinal use of dichlorvos as a
treatment for intestinal parasites (Cervoni
et al. 1969; Pena Chavarria et al. 1969).
These studies have not shown an unusual
increase in sensitivity to the substance. 
Last, regarding the criticism of the limited
study size, the AMVAC study (AMVAC
1997) is only one of hundreds of health
studies of dichlorvos in animals and humans.
The available health data on any substance
should be evaluated as a whole when con-
ducting a risk assessment. 
In summary, although the AMVAC
study (AMVAC 1997) was a relatively small
study, the analytical methods used for mea-
suring both the dose of dichlorvos and RBC
cholinesterase inhibition were state of the
art. The data derived are valid because the
study complied with good laboratory prac-
tices, good clinical practice, and ethical
standards, and should be considered as a
part of the available scientific information
on dichlorvos. 
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Ethical Standards of Studies
Involving Human Subjects
In their letter, Sass and Needleman argue
against the regulatory use of data from
human subjects on both scientific and ethical
grounds. The studies they evaluated were
conducted in accordance with the same ethi-
cal standards that guide all studies involving
human volunteers that are conducted by the
federal government. Sass and Needleman
claim, however, that these studies were not
ethical and should not be used. We would
like to address a common concern regarding
the ethical conduct of these types of studies. 
In a recent publication (Charnley and
Patterson 2003), we reported the results of a
study in which we sought to answer the
question of ethical conduct of clinical pesti-
cide testing performed since 1990 by evalu-
ating whether those studies, performed
according to good clinical practice guidelines
[Food and Drug Administration (FDA)
1997]), provided volunteers with the same
protections afforded volunteers in similar
studies conducted by the federal government
according to the ethical guidelines provided
by the “Federal Policy for the Protection of
Human Subjects,” generally known as the
“Common Rule” [Department of Health
and Human Services (DHHS) 2001].
The Common Rule (DHHS 2001) was
adopted by more than a dozen agencies by
1991, including the U.S. Environmental
Protection Agency (EPA), the Department
of Energy, the Consumer Product Safety
Commission, the Department of Agriculture,
the DHHS, the National Science Foundation,
and other departments that conduct or fund
research involving human subjects. The
U.S. EPA has chosen not to make the pro-
tections of the Common Rule legally
applicable to privately sponsored studies of
regulated substances. 
We evaluated the documentation from
15 recent human studies of 12 insecticides
conducted at four clinical laboratories pro-
vided to us by the pesticide manufacturers,
including those addressed by Needleman
and Sass. The studies we evaluated com-
prised all of the oral pesticide studies sub-
mitted to the U.S. EPA since 1996 and
before the U.S. EPA suspended the use of
human data (along with one earlier study)
for the purpose of tolerance setting. There
were some cases for which we could not ver-
ify compliance with certain Common Rule
elements because the documentation was
unavailable; however, based on our evalua-
tion, it is apparent that the studies we
reviewed were conducted in a manner sub-
stantially consistent with the fundamental
protections of the Common Rule: voluntary
participation, informed consent, and review
by an ethical committee or institutional
review board (which would have considered
and discussed any potentially “scientifically
misleading” protocols).
From this subset of studies, it is evident
that the general practice among the clinical
testing laboratories currently employed by
pesticide manufacturers is to conduct studies
in accordance with the two most commonly
followed ethical guidelines for human stud-
ies by nongovernmental entities, the
Declaration of Helsinki (World Medical
Association 2002) and the international
guidelines for good clinical practice (FDA
1997). In addition, although we noted some
deviations from Common Rule specifics, we
found that the reviewed studies were in sub-
stantial compliance with Common Rule pro-
visos. In the context of the concerns raised
by Sass and Needleman, it is of interest to
point out that good clinical practice specifies
that institutional review board approval be
contingent upon scientifically sound study
design and purpose; the Common Rule
includes no such requirement. 
Standard toxicity testing protocols
using laboratory rodents are considered
adequate for establishing safe exposure
limits for most chemicals under most con-
ditions. Nonetheless, because rodents are
not perfect human surrogates, regulatory
and other organizational guidance for estab-
lishing such exposure limits give priority to
results obtained from observations of
humans. When human observations are
unavailable, results from laboratory animals
are preferred but are treated as uncertain. A
recent study (Dourson et al. 2001) has sug-
gested that, in some cases, failure to use
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may threaten public health because using
only animal data would lead to less stringent
exposure limits for some chemicals than
those that would have been derived on the
basis of human data. When that is the case,
failure to consider ethically obtained human
data for setting limits on pesticide or other
chemical exposures would itself be unethical.
Perhaps some of the concerns about the
ethical conduct of studies conducted by
clinical laboratories for third parties and
submitted to the U.S. EPA might be
avoided if application of the Common Rule
were extended to such studies or if the rec-
ommendation of the National Bioethics
Advisory Commission for a national over-
sight system for all research involving
human subjects were implemented. In any
case, our evaluation has shown that recently
conducted industry-sponsored pesticide
clinical studies were conducted according to
the same ethical standards adhered to by
federally conducted or funded studies.
Needleman and Sass’s contention that those
studies were conducted unethically is not
supported by the available data.
The article by Charnley and Patterson (2003)
was partially supported by the pesticide industry,
which wanted an independent review of its studies.
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this letter, the authors declare they have no compet-
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America on Pesticide Testing
Involving Human Subjects
As the regulatory policy leader of CropLife
America, the national trade association repre-
senting the crop protection industry, I would
like to respond to the letter from Sass and
Needleman, which criticizes human testing
of pesticides.
On 14 December 2001, the U.S.
Environmental Protection Agency (EPA)
commissioned the National Academy of
Sciences (NAS) to examine the “scientific
and ethical issues” posed by the U.S. EPA’s
use of human tests in registering pesticides
and evaluating environmental contaminants
and other chemicals in order to set safe lev-
els of exposure. The NAS position is impor-
tant because the U.S. EPA has conducted
human studies on environmental contami-
nants and other compounds for many years
and requires pesticide registrants to conduct
and submit human testing data such as
worker exposure, biomonitoring, and
pharmacokinetic studies. The U.S. EPA has
a long history of requesting and accepting
industry-sponsored “third-party” human
testing and using these data in its risk
assessment process (U.S. EPA 1998).
Following an intense media campaign
and political pressure by activist groups the
U.S. EPA reversed its policy relative to
industry-sponsored human testing of pesti-
cides in December 2001, without following
applicable legal requirements. In June 2003,
the U.S. Court of Appeals overruled the
U.S. EPA on this matter (CropLife America
et al. v. U.S. EPA 2003), reinstating the
U.S. EPA’s previous practice of 
considering third-party human studies on a case-
by-case basis, applying statutory requirements,
the Common Rule, and high ethical standards as
a guide … until it is replaced by a lawfully pro-
mulgated regulation.
In considering the scientific merits and
ethical acceptability of human studies with
any chemical, medicine, cosmetic, or house-
hold product, it is necessary to consider the
comparative risks and benefits. Crop protec-
tion and other pest control products provide
enormous societal benefits in the form of
plentiful food of high nutritional quality;
reduction in exposure to foodborne aller-
gens, mycotoxins, and other natural toxins;
control of human disease vectors; reduced
need for agricultural land; and reduced need
for manual labor.
The crop protection industry is legally
and ethically bound to provide to govern-
ment regulators the information they need
to judge the safety of products and to set
guidelines for their proper use. Likewise,
the U.S. EPA is bound by law to consider all
“available data” in evaluating the safety of
pesticide use (Food Quality Protection Act of
1996). The vast majority of the toxicity tests
conducted by industry under government
guidelines use laboratory animals or in vitro
procedures. When appropriate, human stud-
ies are conducted to confirm the relevance
of animal data for humans, thus increasing
confidence that the products are safe.
Human volunteer studies with pesticides
are conducted under scientific and ethical
guidelines equivalent to those followed in
phase 1 clinical trials of potential pharma-
ceutical products. Phase 1 trials are also car-
ried out in healthy volunteers who receive
no direct benefit. Results of phase 1 trials are
used to provide assurance that patients can
be treated with safety in subsequent clinical
trials for pharmaceutical efficacy. In both
types of trials, pharmaceutical and pesticide,
and under the required safeguards, the indi-
vidual volunteers accept a small personal risk
for a large societal benefit. An extensive toxi-
cology database is available for pesticides
before any human studies are even consid-
ered. This allows the use of pesticide doses
that can be predicted not to cause adverse
effects, thereby minimizing the risk to vol-
unteers. These scientific points have been
clearly articulated to the NAS committee
examining this issue.
The Joint Meeting on Pesticide Residues
(JMPR) of the World Health Organization
(WHO) and the Food and Agriculture
Organization (FAO) of the United Nations
(FAO 2002) has stated that 
Human data on a pesticide, whether from volun-
teer studies or from other investigations of
human exposures in the workplace or environ-
ment, can be extremely valuable in placing the
animal data in context and, when available,
should always be evaluated even when they are
not used to derive a reference dose. However,
when performing a risk assessment on a pesticide,
the entire database should be considered and the
most appropriate studies and safety factors used
to derive reference values.
The JMPR also emphasized the need to look
at the scientific merit of human studies and
clearly pointed out that human studies must
conform to accepted international standards.
The “Common Rule” (U.S. EPA 1991)
is a well-established, rigorous set of legal, reg-
ulatory, scientific, and ethical guidelines that
regulates research involving human studies
conducted or sponsored by federal govern-
ment agencies and incorporates the princi-
ples set forth by the U.S. Food and Drug
Administration, the WHO, and the World
Medical Association Declaration of Helsinki
(World Medical Association 2002).
The crop protection industry supports
application of the Common Rule to regulate
third-party human clinical trials conducted
and submitted to support pesticide registra-
tions. A thorough review shows that past
studies conducted by industry met the con-
ditions of the Common Rule, although not
specifically required by regulation to do so
(Charnley and Patterson 2003).
Human testing of pesticides is not
intended to determine levels of exposure that
cause adverse effects but rather to confirm
the adequacy of established safe levels of
exposure. This can be achieved in different
ways, depending on the needs of the risk
assessment process. For example, biochemi-
cal markers, such as enzyme inhibition in
blood, might be measured instead of the
effects themselves in other organs such as the
brain. Such data are of immense value in
establishing whether humans are more or less
sensitive than animal species and help to
reduce uncertainty in applying laboratory
data to human exposure.
We believe that abandoning human
testing, as proposed by some groups who
are generally opposed to the use of pesti-
cides and chemicals, would jeopardize
public health and make it more difficult
for regulators to set safe exposure levels for
workers and consumers. Regulators would
be faced with greater uncertainty in assess-
ing potential risks. Using human data, we
can confirm the adequacy and appropriate-
ness of the margin of safety. Lack of appro-
priate data would limit the availability of a
wholesome and safe food supply, as well as
reduce protection from dangerous disease
vectors. Above all, decades of well-consid-
ered legal, regulatory, and scientific proto-
cols requiring human volunteers to assure
the safe development of medicines should
not be ignored in the safe development of
pesticides.
Moreover, it would be unethical to
ignore existing human data per se. The sci-
entific validity of a study and its confor-
mance with ethical standards applicable at
the time it is conducted must be determined
by objective evaluation, not by the identity
of the study’s sponsor, the potential uses of
the material being tested, or the author’s
affiliation. When the weight-of-evidence
approach is used, and it includes data from
studies in humans, allowable levels of expo-
sure may be either increased or decreased
(Dourson et al. 2001).
The author declares he has a competing finan-
cial interest because he is employed by CropLife
America, the national trade association repre-
senting the industry that manufactures and sells
agricultural pesticide products. CropLife
America’s member companies conduct and sub-
mit to the U.S. EPA the research that supports
registration of pesticide products, including the
human clinical trials in question.
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Aldicarb Study Misrepresented
in Human Testing Debate
The pesticide industry is legally and ethically
bound to provide government regulators
with the studies needed to determine that
our products do not cause “unreasonable
adverse effects.” The scientific tests we con-
duct under government guidelines use labo-
ratory animals almost exclusively. In fact,
human studies are not conducted until we
have a good understanding of safe levels of
human exposure based on animal testing.
When appropriate, human studies are con-
ducted to confirm the relevance of animal
data and ultimately increase confidence in
the overall safety assessment. When per-
formed ethically and scientifically, there is
no substitute for the knowledge gained from
these studies. 
In their letter, Sass and Needleman state
that human volunteer studies conducted
with pesticides are scientifically misleading
and are foisted on the U.S. Environmental
Protection Agency (EPA) in order to weaken
regulatory standards. They cite the aldicarb
human studies as one of the examples sup-
porting their position. Bayer CropScience
takes issue with their misrepresentation of
the extensive aldicarb database. 
It is known that aldicarb can cause inhi-
bition of cholinesterase, a well-known bio-
marker of exposure. In fact, all of the animal
and human cholinesterase data generated
over the last 40 years support a no observed
effect level (NOEL) of 0.01–0.025 mg/kg
body weight (bw). The U.S. EPA has relied
on this data to set the reference dose (RfD)
and to assess risk to humans.
Between 1985 and 1988, three separate
incidents of alleged human foodborne poi-
soning from illegal applications of aldicarb to
watermelons and cucumbers occurred in
California (California EPA 1989) and were
reported by Goldman et al. (1990a, 1990b).
The authors attempted to derive exposure
estimates for these alleged aldicarb incidents
from average body weights, self-reports of
symptoms and consumption, and average
aldicarb residues from those watermelons and
cucumbers that were available for analysis.
Specifically, the authors’ questionable deriva-
tion of high consumption levels deliberately
biased toxicity estimates. The description of
cases used for estimates was very limited in
terms of onset, duration, and severity. Many
of the symptoms of cholinesterase inhibition
were nonspecific and difficult to diagnose in
the onset of illness. 
In 1991, the U.S. EPA considered that
the incident data were not consistent with
results from a human study conducted in
1971 and that they indicated that the animal
studies might not be predictive of the human
response. Thus the agency revised the RfD
from 0.001 to 0.0002 mg/kg bw/day. 
Following the U.S. EPA’s decision 
to revise the RfD, the New England
Epidemiology Institute (Rothman et al.
1991) reviewed the articles by Goldman
et al. (1990a, 1990b) and concluded that
they “… form an inappropriate foundation
for establishing a reference dose.” 
Taking into account these events, Bayer
CropScience concluded that reliable human
data would be necessary to refine the dose
response and time course of cholinesterase
inhibition following exposure to aldicarb
and to further investigate the relative sensi-
tivity of humans compared to animals. 
The 1992 aldicarb human volunteer
(double blind) study was conducted at
Inveresk Clinical Laboratories in Edinburgh,
Scotland (Wyld et al. 1992) according to all
of the recommended scientific and ethical
guidelines that were in place at the time of
the study. Inveresk is a well known experi-
mental laboratory experienced in conduct-
ing both human and animal studies. Before
the study was initiated, the Ethics Review
Board of Inveresk Clinical Laboratories
approved the study design and objectives.
The candidates were all prescreened and
given physical examinations. Their per-
sonal physicians were also consulted for
any medical reasons that might preclude an
individual’s participation in the study.
Information sheets on the profile of aldicarb
were given and explained to the candidates.
Informed consent forms were then given to
and signed by all study participants. 
No serious adverse effects occurred in
this study. One male subject (0.075 mg/kg
bw group) developed profuse sweating,
which was reported to be related to aldicarb.
Of the remaining 23 symptoms reported,
almost half were noted in the placebo group
(22 individuals), whereas the others were
either not related to the expected time
course of symptoms, not consistent with
symptoms associated with cholinesterase
inhibition, or were noted among the
remaining 35 individuals. Thus, the NOEL
for clinical symptoms was 0.05 mg/kg bw
and the NOEL based on inhibition of RBC
was 0.025 mg/kg bw (Figure 1).
In 1992, Bayer CropScience submitted
the human volunteer study (Wyld et al.
1992) to the U.S. EPA. The agency reviewed
the aldicarb human study and determined
that it was acceptable and that it was a key
study to set the RfD (U.S. EPA 1992). The
U.S. EPA determined the overall NOEL in
this study to be 0.01 mg/kg bw/day, con-
firming the NOEL established in multiple
animal studies. The RfD was reestablished
at 0.001 mg/kg bw/day. The U.S. EPA has
used this RfD to assess risk since 1992. In
addition, the agency also had the study
reviewed by a Joint Science Advisory
Panel/Science Advisory Board in 1992 (U.S.
EPA 1992) and they also determined the
study to be acceptable and appropriate for
use in the risk assessment process. The 1998
U.S. EPA panel reaffirmed the use of the
data in the risk assessment process. Also, the
panel addressed additional questions or
other matters concerning aldicarb. These
critical facts have been omitted by Sass and
Needleman and lead the reader to draw con-
clusions that the human study was never
reviewed and accepted by the U.S. EPA and
its joint advisory panels.
In conclusion, good science and the law
(Federal Food, Drug, and Cosmetic Act
1997; Federal Inssecticide, Fungicide and
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Figure 1. Time course of mean red blood cell
cholinesterase inhibition after aldicarb exposure.
●
16.3
14.7
13.1
11.5
9.9
8.3
6.7
5.1
–20 –10 0 10 20 30
Time (hr)
A
c
t
i
v
i
t
y
 
(
I
U
/
m
L
)
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
● ●
●●
●
● ●
●
● ●
●
●
●
● ● ● ●
●
● ●●● ● ●
●
Control
0.01 mg/kg
0.025 mg/kg
0.05 mg/kg
0.075 mg/kg
●
●
●
●
●Rodenticide Act 1972; Food Quality protec-
tions Act of 1996) require the U.S. EPA to
consider all credible data when making regu-
latory decisions. The aldicarb human study
conducted in 1992 (Wyld et al. 1992) was
essential in confirming the relevance of the
existing animal database and refining the risk
assessment. The weight given to any particu-
lar study or data set (human or animal) can
vary depending on its scientific merit, but no
valid study or data set should be discounted
from the evaluation process on the basis of
personal and emotional arguments.
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CLARIFICATION
Readers of the February Spheres of
Influence article (“Does Secrecy
Equal Security? Limiting Access to
Environmental Information,” EHP
112:A104–A107 (2004)] may have
inferred that at the time Christopher
Gozdor represented the Aberdeen cit-
izens group, he was working for his
present employer, the University of
Maryland Center for Health and
Homeland Security. In fact, Gozdor
was a student attorney with the uni-
versity’s Environmental Law Clinic at
the time he represented the group. 